CORT vs. PRGO, HRMY, TARO, SUPN, XNCR, PCRX, OPK, ADCT, AVIR, and JAZZ
Should you be buying Corcept Therapeutics stock or one of its competitors? The main competitors of Corcept Therapeutics include Perrigo (PRGO), Harmony Biosciences (HRMY), Taro Pharmaceutical Industries (TARO), Supernus Pharmaceuticals (SUPN), Xencor (XNCR), Pacira BioSciences (PCRX), OPKO Health (OPK), ADC Therapeutics (ADCT), Atea Pharmaceuticals (AVIR), and Jazz Pharmaceuticals (JAZZ). These companies are all part of the "pharmaceutical preparations" industry.
Corcept Therapeutics (NASDAQ:CORT) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, community ranking, profitability, valuation, institutional ownership and risk.
Corcept Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.
Corcept Therapeutics has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
Corcept Therapeutics has a net margin of 22.38% compared to Perrigo's net margin of -0.17%. Corcept Therapeutics' return on equity of 24.19% beat Perrigo's return on equity.
Perrigo received 239 more outperform votes than Corcept Therapeutics when rated by MarketBeat users. However, 70.62% of users gave Corcept Therapeutics an outperform vote while only 66.75% of users gave Perrigo an outperform vote.
In the previous week, Corcept Therapeutics had 11 more articles in the media than Perrigo. MarketBeat recorded 16 mentions for Corcept Therapeutics and 5 mentions for Perrigo. Corcept Therapeutics' average media sentiment score of 0.90 beat Perrigo's score of 0.90 indicating that Corcept Therapeutics is being referred to more favorably in the media.
93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 20.5% of Corcept Therapeutics shares are held by insiders. Comparatively, 0.7% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Corcept Therapeutics currently has a consensus price target of $40.10, suggesting a potential upside of 43.32%. Perrigo has a consensus price target of $40.67, suggesting a potential upside of 41.99%. Given Corcept Therapeutics' higher probable upside, research analysts plainly believe Corcept Therapeutics is more favorable than Perrigo.
Summary
Corcept Therapeutics beats Perrigo on 13 of the 17 factors compared between the two stocks.
Get Corcept Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corcept Therapeutics Competitors List
Related Companies and Tools
